Infant Bacterial Therapeutics AB (IBT.B) AI Stock Analysis

• Market Cap: kr687.04M
• Dividend Yield: N/A
• Average Volume (3M): 13.37K
• Price to Earnings (P/E): ―
• Beta (1Y): -0.19
• Revenue Growth: N/A
• EPS Growth: 44.65%
• Country: SE
• Employees: 8
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -1.43
• Shares Outstanding: 13,018,137
• 10 Day Avg. Volume: 5,917
• 30 Day Avg. Volume: 13,366
• PEG Ratio: -2.50
• Price to Book (P/B): 4.24
• Price to Sales (P/S): 180517.03
• P/FCF Ratio: -6.38
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 46 Neutral
• Price Target: kr48.00 ▼(-23.81% Downside)
• Action: Reiterated Date: 12/30/25
• Date: Action: Reiterated 12/30/25

The score is driven primarily by weak financial performance (persistent losses and negative cash flow with increasing burn), partially mitigated by a debt-free balance sheet. Technicals are mixed with neutral momentum but a broader downtrend versus longer-term averages, and valuation is constrained by negative earnings and no dividend support.

Infant Bacterial Therapeutics AB Business Overview & Revenue Model

Company Description

Infant Bacterial Therapeutics AB (IBT.B) is a Swedish biopharmaceutical company focused on developing and commercializing drugs to prevent or treat diseases affecting premature infants. The company operates primarily in the healthcare and biotechnology sectors, with a core emphasis on leveraging its expertise in bacterial therapy to address unmet medical needs in neonatology. Its leading product candidate, IBP-9414, targets the prevention of necrotizing enterocolitis (NEC) in preterm infants, aiming to provide innovative solutions to improve infant health outcomes.

How the Company Makes Money

Infant Bacterial Therapeutics AB generates revenue primarily through the development and commercialization of its pharmaceutical products. The company's revenue model is centered around licensing agreements, research and development collaborations, and eventual sales of its therapeutic products once they receive regulatory approval. Key revenue streams include upfront payments, milestone payments, and royalties from partners involved in the commercialization and distribution of its products. Significant partnerships with larger pharmaceutical companies or research institutions can also contribute to its earnings, providing access to additional resources and markets, which is crucial for advancing its product pipeline and achieving commercial success.

Infant Bacterial Therapeutics AB Financial Statement Overview

Summary

Overall financial profile is weak: minimal and volatile revenue, large and widening losses, and consistently negative operating/free cash flow with rising burn. The main offset is a debt-free balance sheet, but equity has declined materially over time, increasing future financing/dilution risk.

Income Statement

The income statement remains very weak, reflecting a pre-commercial biotech profile. Revenue is minimal and volatile (2024 revenue fell ~20% vs. 2023), while losses are large and widening versus earlier years (net loss roughly -137m in 2024 vs. -65m in 2022). Profitability is consistently negative with extremely weak net margins, indicating the cost base is far ahead of the current revenue run-rate. A key positive is that reported gross profit equals revenue in years with sales, but this is not enough to offset heavy operating expenses.

Balance Sheet

The balance sheet is a relative strength: the company reports zero debt across all years shown, resulting in no leverage pressure and high financial flexibility. However, equity has declined materially over time (from ~510m in 2019 to ~170m in 2024), reflecting cumulative losses and ongoing cash burn, and returns on equity are consistently negative (worsening to about -0.80 in 2024). Overall, solvency looks strong due to no debt, but the shrinking equity base highlights dilution/runway risk if losses persist.

Cash Flow

Cash flow quality is weak, with operating cash flow and free cash flow negative every year shown, consistent with a company funding R&D and operations without meaningful recurring revenue. Cash burn has generally increased from earlier years (about -51m in 2019 to about -113m in 2024), and free cash flow growth is negative in most years, including a sharp decline in 2024. A modest positive is that free cash flow and net income move closely together (both negative), but the overall trajectory still indicates sustained funding needs.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	-1.00K	4.00K	77.00K	12.00K	0.00	0.00
Gross Profit	-1.00K	4.00K	77.00K	12.00K	0.00	0.00
EBITDA	-101.51M	-136.91M	11.55M	-64.34M	-43.76M	-70.89M
Net Income	-102.33M	-136.91M	-123.07M	-65.45M	-44.99M	-72.31M
Balance Sheet
Total Assets	193.23M	239.57M	351.33M	349.62M	408.48M	450.32M
Cash, Cash Equivalents and Short-Term Investments	176.32M	223.39M	329.06M	335.84M	386.75M	423.44M
Total Debt	0.00	0.00	0.00	0.00	0.00	0.00
Total Liabilities	58.88M	69.30M	46.18M	17.91M	13.22M	10.16M
Stockholders Equity	134.35M	170.26M	305.15M	331.71M	395.25M	440.15M
Cash Flow
Free Cash Flow	-102.84M	-113.13M	-101.22M	-85.80M	-55.62M	-58.39M
Operating Cash Flow	-102.84M	-113.13M	-101.22M	-85.80M	-55.62M	-58.39M
Investing Cash Flow	0.00	0.00	-4.15M	-1.00K	0.00	0.00
Financing Cash Flow	0.00	2.01M	96.52M	1.88M	91.00K	1.76M

Infant Bacterial Therapeutics AB Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 63.00
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:IBT.B, the sentiment is Negative. The current price of 63 is above the 20-day moving average (MA) of 53.23, above the 50-day MA of 50.43, and above the 200-day MA of 55.28, indicating a bearish trend. The MACD of -0.23 indicates Positive momentum. The RSI at 43.10 is Neutral, neither overbought nor oversold. The STOCH value of 32.62 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:IBT.B.

Infant Bacterial Therapeutics AB Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CANTA	55 Neutral	€1.07B	7.07	81.19%	―	―	―
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
IBT.B	46 Neutral	kr687.04M	-10.44	-46.42%	―	―	44.65%
XBRANE	46 Neutral	kr122.00M	121.99	-16.90%	―	4.64%	―
ACE	44 Neutral	kr364.11M	-6.44	-79.60%	―	―	31.62%
IMMU	43 Neutral	kr248.30M	-1.89	-16.51%	―	―	31.37%
GUARD	42 Neutral	kr32.27M	-0.24	-199.25%	―	―	0.30%

Infant Bacterial Therapeutics AB Corporate Events

Infant Bacterial Therapeutics Partners with BioConnection for Drug Production

Infant Bacterial Therapeutics AB has partnered with BioConnection to advance the production of their lead drug, IBP-9414, by initiating Process Performance Qualification at BioConnection’s facility in the Netherlands. This collaboration is crucial for securing IBT’s commercial supply chain and supports their market expansion, as BioConnection’s capabilities align with IBT’s mission to provide innovative therapies for premature infants, potentially saving lives and addressing unmet medical needs.

IBT Pursues Accelerated Approval for IBP-9414 After FDA Discussions

Infant Bacterial Therapeutics AB has decided to pursue an accelerated approval pathway for its live biotherapeutic product, IBP-9414, following discussions with the FDA. This decision allows for expedited approval of the drug, which has shown significant potential in reducing mortality among premature infants. The company plans to apply for marketing authorization in the USA by the first half of 2026, with the validation of the manufacturing process currently underway. The accelerated approval pathway reflects IBT’s commitment to addressing unmet medical needs in the field of neonatal care.

Infant Bacterial Therapeutics Partners with Recipharm for IBP-9414 Production

Infant Bacterial Therapeutics AB has partnered with Recipharm Advanced Bio to initiate the Process Performance Qualification (PPQ) for its lead product, IBP-9414, at Recipharm’s facility in Cuxhaven, Germany. This collaboration marks a significant milestone in IBT’s journey to bring IBP-9414 to market, with the potential to save over 1,000 lives annually in the US alone. The partnership underscores both companies’ commitment to addressing unmet medical needs in vulnerable populations and strengthens IBT’s commercial supply chain capabilities.

Infant Bacterial Therapeutics Advances IBP-9414 Amid Financial Challenges

Infant Bacterial Therapeutics AB reported no net sales and a reduced operating loss for the third quarter of 2025, reflecting ongoing investment in their lead product, IBP-9414. The company achieved a significant milestone with the FDA granting Breakthrough Therapy Designation for IBP-9414, which showed a 27% reduction in mortality in a Phase 3 study. Efforts are underway to secure market approval in the US and Europe, with plans to submit a Biological License Application in 2026, positioning the company for potential market entry and partnerships for global distribution.

Infant Bacterial Therapeutics AB Forms Nomination Committee for 2026 AGM

Infant Bacterial Therapeutics AB has announced the formation of its Nomination Committee for the 2026 Annual General Meeting. The committee, which includes representatives from the company’s three largest shareholders, will play a crucial role in shaping the company’s leadership and strategic direction, potentially impacting its market positioning and stakeholder interests.